United States Meningococcal Vaccines Market Outlook 2025 | Novel Conjugate Vaccines Targeting Multiple Serogroups in Phase II/III Trials

Meningococcal Vaccine Market Size reached US$ 3.47 Billion in 2024 and is expected to reach US$ 6.05 Billion by 2033, growing at a CAGR of 6.4% during the forecast period 2025-2033.

The meningococcal vaccines market focuses on immunizations against Neisseria meningitidis, the bacteria responsible for meningitis and septicemia. Vaccines prevent outbreaks and reduce mortality associated with the disease. Both conjugate and polysaccharide vaccines are widely used globally. Government vaccination programs and rising awareness drive market growth. Ongoing research aims to develop broader-spectrum vaccines covering multiple serogroups.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Meningococcal Vaccines Market Landscape:- https://datamintelligence.com/download-sample/meningococcal-vaccines-market?rk

☛ Meningococcal Vaccines Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In August 2025, Pfizer received FDA approval for an updated MenB vaccine targeting emerging Neisseria meningitidis strains. The vaccine is expected to enhance protection for adolescents and young adults in outbreak-prone regions.

✅ In July 2025, GlaxoSmithKline (GSK) launched a nationwide campaign to promote booster doses of its MenACWY conjugate vaccine among college students. Early uptake indicates improved vaccination coverage in high-risk populations.

✅ In June 2025, Sanofi Pasteur announced clinical trial results showing that its quadrivalent meningococcal vaccine demonstrates extended immunity for up to five years, supporting long-term protection strategies in adolescents.

Europe: Recent Industry Developments

✅ In July 2025, Bavarian Nordic initiated a Phase 3 trial in Germany for a novel MenB vaccine formulation designed for broader strain coverage across Europe. The trial aims to address regional epidemiological variations in meningococcal disease.

✅ In June 2025, Pfizer expanded its meningococcal vaccination program in the UK, targeting at-risk populations including university students and immunocompromised adults. The program focuses on public awareness and easy access to vaccination.

✅ In May 2025, GSK received EMA approval for its MenACWY booster for adults, enabling enhanced protection for travelers and populations with seasonal outbreak risk.

Japan: Recent Industry Developments

✅ In July 2025, Takeda Pharmaceutical began post-marketing surveillance for its MenB vaccine, assessing long-term safety and immune response in Japanese adolescents.

✅ In June 2025, Astellas Pharma partnered with local healthcare authorities to improve meningococcal vaccine awareness in schools and universities, aiming to increase vaccination coverage among teenagers.

✅ In May 2025, Shionogi & Co. announced the development of a novel quadrivalent meningococcal vaccine with enhanced efficacy against regional serogroups, expected to enter clinical trials in late 2025.

☛ Meningococcal Vaccines Market Trends:

Conjugate vaccines and quadrivalent formulations are replacing polysaccharide vaccines for better immunity. Global vaccination programs are expanding, especially in Africa and Asia. Combination vaccines with other pediatric immunizations are increasing compliance. New adjuvants are being developed to enhance immune response. Outbreak preparedness and travel vaccines are fueling demand.

Recent Pipelines:

Novel conjugate vaccines targeting multiple serogroups are in phase II/III trials. mRNA-based meningococcal vaccines are under preclinical evaluation. Combination vaccines with Hib or pneumococcal vaccines are being developed. Adjuvant formulations to boost long-term immunity are being tested. Vaccine candidates for adolescents and adults are expanding in clinical studies.

☛ Meningococcal Vaccines Market Competitve Landscape:

Sanofi S.A., GlaxoSmithKline Inc., Merck & Co., Inc., Pfizer Inc., Bio-Med (P) Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co., Ltd., and Incepta Pharmaceuticals Ltd., among others.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/meningococcal-vaccines-market

☛ Segment Covered in the Meningococcal Vaccines Market:

Type: Monovalent | Quadrivalent | Bivalent | Others

Product Type: Polysaccharide Meningococcal Vaccines | Conjugate Meningococcal Vaccines | Serogroup Meningococcal Vaccines

End-User: Hospitals | Specialty Clinics | Public Health Agencies | Others

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Meningococcal Vaccines Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=meningococcal-vaccines-market

☛ Regional Analysis for Meningococcal Vaccines Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ Frequently asked questions:

➠ What is the global sales, production, consumption, import, and export value of the Meningococcal Vaccines Market?
➠ Who are the key global manufacturers, and what is their operational performance?
➠ What are the major opportunities and threats in the global Meningococcal Vaccines Market?
➠ Which product types or end-users show the most growth potential and market share?
➠ What challenges and constraints are impacting the Meningococcal Vaccines Market?
➠ What sales, marketing, and distribution channels are used globally?

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.